

# The Kalimantacin/Batumin Biosynthesis Operon Encodes a Self-Resistance Isoform of the FabI Bacterial Target

Wesley Mattheus,<sup>1</sup> Joleen Masschelein,<sup>1</sup> Ling-Jie Gao,<sup>2</sup> Piet Herdewijn,<sup>2</sup> Bart Landuyt,<sup>3</sup> Guido Volckaert,<sup>1</sup> and Rob Lavigne<sup>1,\*</sup>

<sup>1</sup>Laboratory of Gene Technology, Katholieke Universiteit Leuven, Kasteelpark Arenberg 21 box 2462, Leuven, B-3001, Belgium

<sup>2</sup>Interface Valorization Platform, Katholieke Universiteit Leuven, Kapucijnenvoer 33 block i box 7001, Leuven, B-3000, Belgium

<sup>3</sup>Animal Physiology and Neurobiology Section, Katholieke Universiteit Leuven, Naamsestraat 59 - box 2465, Leuven, B-3000, Belgium

\*Correspondence: rob.lavigne@biw.kuleuven.be

DOI 10.1016/j.chembiol.2010.07.015

## SUMMARY

BatG is a trans-2-enoyl-ACP reductase, encoded in the kalimantacin/batumin (kal/bat) biosynthesis operon. It is not essential for the production of the kal/bat secondary metabolite. Instead, BatG is an isoform of FabI, conferring full resistance to target bacteria. It also complements FabI in its role in fatty acid biosynthesis. The identification of FabI as the antibacterial target is important to assess clinical potential of the kalimantacin/batumin antibiotics against *Staphylococcus aureus*.

## INTRODUCTION

Bacteria produce fatty acids through a type II system (FASII). Each reaction is catalyzed by a discrete enzyme. The FASII pathway is essential to cell growth and the trans-2-enoyl reductase is responsible for the final and rate-limiting step in each cycle. As such, this enzyme is essential for the viability of bacteria (Heath and Rock, 1995). Since the initially identified trans-2-enoyl reductase FabI (e.g., *Escherichia coli*, *S. aureus*), other FabI isozymes were discovered in other species, such as FabL and FabK in *Bacillus subtilis* and *Streptococcus pneumoniae*, respectively (Heath and Rock, 2000; Heath et al., 2000). Recently, reports on yet another FabI isoform (FabV) were published from *Vibrio cholerae* (Massengo-Triassé and Cronan, 2008), *Pseudomonas aeruginosa* (Zhu et al., 2010), and *Burkholderia mallei* (Lu and Tonge, 2010). These isoforms show only weak sequence homology with other trans-2-enoyl reductases.

Given their selectivity for bacteria over mammals and the highly conserved FASII system between species, fatty acid inhibitors have long been undisputedly potent antibacterial compounds (Payne et al., 2002). Several antibiotics target bacterial fatty acid synthesis, three of which (Triclosan, diazaborines, and isoniazid) target the trans-2-enoyl-ACP reductase (FabI) (Heath et al., 2002). However, in recent reports their potential in clinical settings has been hotly debated. Brinster et al. (2009) showed that major Gram-positive pathogens can overcome FASII inhibition through exogenous fatty acid incorporation. On

the other hand, others invalidated these results for *S. aureus* and showed that FabI inhibitors do work in vivo (Balemans et al., 2010).

Methicillin-resistant *Staphylococcus aureus* (MRSA) represents a major threat in both hospital and community settings, since it is developing resistance to the so called “last-line” antibiotic vancomycin. To combat this emerging antibiotic resistance of pathogenic bacteria, new antibacterial agents are needed. The kalimantacin antibiotics are promising novel antibacterial agents with a strong selective antistaphylococcal activity (0.05 µg/ml) and moderate activity against enterobacteria (1–10 µg/ml) (Kamigiri et al., 1996). The kalimantacin antibiotics were isolated from a fermentation broth of *Alcaligenes sp.* YL-02632S (Kamigiri et al., 1996; Tokunaga et al., 1996). Batumin, a compound with the same gross molecular composition as kalimantacin A, has been isolated from a fermentation broth of *Pseudomonas batumici* (Smirnov et al., 2000). To date, no batumin-resistant clinical *Staphylococcus* isolates were reported (Klochko et al., 2008) and the mechanism of action of these antibacterial compounds has not yet been reported. However, batumin influences cell wall morphology, causing the peripheral wall to differentiate into an outer and inner layer (primary and secondary wall, respectively; Giesbrecht et al., 1998).

Recently, we reported the isolation of kalimantacin/batumin (kal/bat) from *P. fluorescens* strain BCCM\_ID9359 and experimentally elucidated its biosynthesis gene cluster (Mattheus et al., 2010). High-resolution MS, <sup>1</sup>H, and <sup>13</sup>C NMR spectra data verified the polyketide structure (Figure 1) as reported for kalimantacinA/batumin (Mattheus et al., 2010). The kal/bat gene cluster consists of 16 open reading frames (ORFs), encoding a collinear hybrid PKS-NRPS system (Bat1-3), extended by *trans*-acting tailoring functions (BatA-M). We here report that BatG encodes a functional FabI isozyme which confers full resistance to kalimantacin/batumin and complements FabI, marking this enzyme as the bacterial target for these antibiotics.

## RESULTS AND DISCUSSION

### Bioinformatical Analysis Reveals BatG as a Predicted Trans-2-Enoyl-ACP Reductase Isozyme

Initial similarity searches revealed BatG similarity to trans-2-enoyl-ACP reductases, involved in the formation of a saturated acyl-ACP by an NAD(P)H-dependent reduction of the trans-2-enoyl-ACP



**Table 1. MIC Values**

Strain	MIC ( $\mu\text{g/ml}$ )			
	Kal/Bat			Triclosan
	MH + 2% glucose	MH + [0–0.01 mM IPTG]	MH + [0.1–1 mM IPTG]	MH + 0.5 mM IPTG
<i>E. coli</i> S17-1	4	2	2	0.1
<i>E. coli</i> S17-1+pJH10	1	1	1	0.1
<i>E. coli</i> S17-1 +pJH10_BatG	1	1	>128	32
<i>E. coli</i> S17-1 +pSK5632_BatG	>128	>128	>128	32
<i>P. fluorescens</i> Pf5	2	2	2	64
<i>P. fluorescens</i> Pf5 +pJH10_BatG	>128	>128	>128	64
<i>P. fluorescens</i> BCCM_ID9359_ΔBatG	>128	>128	>128	64
<i>S. aureus</i> RN4220	0.1	0.1	0.1	0.1
<i>S. aureus</i> RN4220 + pSK5632_BatG	>128	>128	>128	64

Minimal inhibitory concentrations were determined using NCCLS standards (National Committee for Clinical Laboratory Standards, document M7-A5). pSK5632: ApR, CmR,  $\theta$ eta replication, Plac. pJH10: TcR, SmR, oriT, Ptac, lacIq. pSK5632 results in constitutive expression in both *E. coli*, *P. fluorescens*, and *S. aureus*. To control the tac-promotor regulated expression of pJH10\_BatG in *E. coli*, glucose (2%) or varying IPTG concentrations [1  $\mu\text{M}$ –1 mM] were added. pJH10 is constitutively expressed in *P. fluorescens*, as shown in other expression experiments (Mattheus et al., 2010).

### Heterologous BatG Expression Provides Complete Resistance to kal/bat in Sensitive Strains and Complements FabI as an Essential Enzyme in Fatty Acid Biosynthesis

Expression of BatG in *trans*, using the broad-host-range IncQ expression vector pJH10 (El-sayed et al., 2001), in both *P. fluorescens* pf5 and *E. coli* S17-1 results in a pronounced increase of the MIC, from 2  $\mu\text{g/ml}$  to complete resistance to kal/bat (MIC > 128  $\mu\text{g/ml}$ ) (Table 1). Expression of BatG in *S. aureus* RN4220 (using the low-copy-number shuttle vector pSK5632; Grkovic et al., 2003) also confers complete resistance to batumin (MIC from 0.05 to >128  $\mu\text{g/ml}$ ). Variation in BatG expression level by controlled IPTG induction rules out a dose dependent effect, indicating that the resistance is due to the expression of the kal/bat-resistant BatG rather than overexpression of the target. BatG expression also confers resistance to triclosan, another FabI inhibitor, with MIC drastically increasing from 0.064 to 32  $\mu\text{g/ml}$  and 64  $\mu\text{g/ml}$  for *E. coli* and *S. aureus*, respectively (Table 1). This further indicates a common antibacterial target of kal/bat and triclosan.

To test whether BatG can functionally complement FabI, the expression plasmid was introduced into the *E. coli fabI(Ts)* strain JP1111 (Egan and Russell, 1973). This strain is unable to grow at the nonpermissive temperature of 42°C due to the *fabI392* mutation. JP1111 strains complemented with BatG grow at 42°C, whereas strains carrying the vector do not (Figure 3). Thus, BatG functionally complements the *E. coli fabI* mutation, showing its *in vivo* trans-2-enoyl-ACP reductase activity.

Correlating these data to the previously described host spectrum of activity of kal/bat (Mattheus et al., 2010) suggests that species which rely solely on FabI homologs for their fatty acid synthesis (*S. aureus*, *E. coli*) are effectively inhibited, while strains with an alternative trans-2-enoyl-ACP reductase isoforms (*B. subtilis*, *P. aeruginosa*, *S. pneumoniae*) are resistant to kal/bat.


### Conclusions

Kal/bat has a strong antistaphylococcal activity with a MIC of 0.05  $\mu\text{g/ml}$ , making it a potent new antibiotic to cope with resis-

tant *S. aureus* (MRSA) infections. The results presented here prove that kal/bat antibacterial activity is caused by FabI trans-2-enoyl-ACP reductase inhibition during fatty acid biosynthesis, a highly relevant and intensely discussed antibacterial target. The trans-2-enoyl-ACP reductase isoform BatG is resistant to both kal/bat and triclosan inhibition. The broad-host-range complementation capability of this natural enzyme (*P. fluorescens*, *E. coli*, and *S. aureus*) suggests a potential and unwanted source of resistance against FabI inhibitors in clinical settings. Hence, these findings are important for future research on FabI as an antibacterial target and for clinical potential of the kalimantacin/batumin-related antibiotics against MRSA.

### SIGNIFICANCE

**To combat the emerging antibiotic resistance of pathogenic bacteria like methicillin-resistant *Staphylococcus aureus* (MRSA), a critical pathogen in hospital environments, new**



**Figure 3. Growth of *E. coli* JP1111 FabI(Ts) Strain Complemented with BatG**

BatG was cloned into pJH10 low copy number vector under control of the tac promoter. Both empty vector (pJH10) and construct (pJH10\_BatG) were transformed into FabI(Ts) strain JP1111. Serial 10-fold dilutions of each overnight culture were spotted on plates of LB supplemented with 0.5 mM IPTG and incubated at 30°C (left) and 42°C (right), respectively.

potential antibacterial agents (like the kalimantacin antibiotics) are being investigated. In this report, we show that the kalimantacin antibiotics inhibit bacterial fatty acid synthesis (FASII pathway) and we describe a natural resistance gene. These results have strong implications for the clinical potential of the kalimantacin antibiotics, since the essential nature of the FASII pathway in Gram-positive pathogens is currently under debate.

## EXPERIMENTAL PROCEDURES

### Bacterial Strains, Plasmids, and Culture Conditions

*P. fluorescens* strain BCCM\_ID9359 was used as the wild-type kal/bat producer. The strain was grown at 28°C in tryptose broth (Merck, Germany) for liquid cultivation and on tryptose agar (Merck) for solid cultivation. *E. coli* Transformax EC100 (Epicenter, US) was used for plasmid preparations, *E. coli* S17-1 was used for conjugal transfer of DNA into *P. fluorescens* strain BCCM\_ID9359. *E. coli* strain JP1111 was obtained from the Coli Genetic Stock Center (CGSC, Yale University). Strains were grown at 37°C in lysogeny broth (LB) and LB agar (LB supplemented with 1.5% w/v agar). *S. aureus* ATCC6538 was used in bioassays to monitor kal/bat production. Media were supplemented with one or more antibiotics at appropriate concentrations: ampicillin (100 mg/l), kanamycin (50 mg/l), triclosan (25 mg/l), tetracycline (15 mg/l). Plasmids used during this work are listed in Table S1.

### Production, Isolation, and Analysis of kal/bat

*P. fluorescens* strain BCCM\_ID9359 was seeded in 250 ml tryptose broth in a 1 L Erlenmeyer flask and incubated at 16°C on a rotatory shaker (200 rpm) for 48 hr. To isolate kal/bat, the culture was adjusted to pH 10 with NaOH, and the cells removed by centrifugation. After acidification with formic acid to pH 3, the supernatant was extracted with chloroform (2 × 250 ml) and concentrated in vacuo. The extract was either used directly for HPLC analysis or further purified by silica gel column chromatography. The HPLC analysis was carried out on an Alltima C-18 column (5 μm, 250 × 4.6 mm, Alltech). The column was equilibrated with 100% solvent A (5% acetonitrile (ACN), 0.1% TFA) and developed according to the following program: (0–1 min, 100% A; 1–30 min, a linear gradient from 100% A to 100% ACN; 30–40 min, linear gradient from 100% ACN to 100% A) at a flow rate of 1 ml/min and UV detection at 228 nm using a Shimadzu SPD-10A detector.

Silica gel column chromatography (20 × 250 mm; CH<sub>2</sub>Cl<sub>2</sub>/MeOH/HCOOH (100/4/0.1 to 100/10/0.1) was used for large scale purification prior to NMR analysis and microbiological testing. MS analysis was performed on a Bruker Daltonics Apex-Qe FT mass spectrometer and NMR on a Bruker Ultrashield Avance instrument, operating at 600/300 MHz for <sup>1</sup>H and 150/75 MHz for <sup>13</sup>C nuclei in CDCl<sub>3</sub>.

### Targeted Inactivation

Directed, in-frame gene deletion of BatG was achieved by cloning two DNA fragments of approximately 300–500 bp flanking *BatG* into the suicide vector pAKE604 (El-sayed et al., 2001) (pAKE604\_BatG; primers are listed in Table S1). DNA transfer to *P. fluorescens* strain BCCM\_ID9359 was performed through biparental mating with *E. coli* S17-1. A late exponential culture of *E. coli* harboring the relevant plasmid and *P. fluorescens* strain BCCM\_ID9359 were mixed on a 0.45 μm sterile Millipore filter, placed on an LB-agar plate. After overnight incubation at 28°C, the mixture was resuspended in 1 ml of saline solution and spread on LB-agar plates supplemented with plasmid-selected antibiotic and triclosan. Cointegrant clones were picked and incubated in tryptose broth without selection overnight at 30°C. Serial dilutions were spread on tryptose plates containing 5% sucrose, to select for vector excision. Deletion knockouts were screened by replica plating and PCR analysis.

### Heterologous BatG Expression

The BatG open reading frame was amplified and cloned into pJH10 (El-sayed et al., 2001) under control of the *tac* promoter (pJH10\_BatG). For

BatG, the difference in G+C-content between Gram-positive and Gram-negative bacteria, expression (transcription, translation) of high G+C-content genes in Gram-negative bacteria did not cause a problem: BatG and its upstream region was amplified and cloned into the low-copy-number *S. aureus* shuttle vector pSK5632 (Grkovic et al., 2003) (pSK5632\_BatG) (primers are listed in Table S1). DNA transfer to *P. fluorescens* was performed through biparental mating with *E. coli* S17-1. *S. aureus* RN4220 was transformed with pSK5632\_BatG by electroporation as described by Schenk and Laddaga (1992). Expression of BatG was induced by varying IPTG concentrations (1 μM to 1 mM) to examine an expression dose-dependent effect.

## SUPPLEMENTAL INFORMATION

Supplemental Information includes two figures and one table and can be found with this article online at doi:10.1016/j.chembiol.2010.07.015.

## ACKNOWLEDGMENTS

We acknowledge the Coli Genetic Stock Center for *E. coli* strain JP1111, Christopher M. Thomas for vectors pAKE604 and pJH10 and Jodi Lindsay for vector pSK5632. B.L. thanks the Flemish Government for the financing of the mass spectrometry facility ProMeta.

Received: March 15, 2010

Revised: June 20, 2010

Accepted: July 13, 2010

Published: October 28, 2010

## REFERENCES

- Balemans, W., Lounis, N., Gilissen, R., Guillemont, J., Simmen, K., Andries, K., and Koul, A. (2010). Essentiality of FASII pathway for *Staphylococcus aureus*. *Nature* 463, E3–E4.
- Brinster, S., Lamberet, G., Staels, B., Trieu-Cuot, P., Gruss, A., and Poyart, C. (2009). Type II fatty acid synthesis is not a suitable antibiotic target for Gram-positive pathogens. *Nature* 458, 83–86.
- Egan, A.F., and Russell, R.R.B. (1973). Conditional mutations affecting the cell envelope of *Escherichia coli* K-12. *Genet. Res.* 21, 139–152.
- El-sayed, A.K., Hothersall, J., and Thomas, C.M. (2001). Quorum-sensing-dependent regulation of biosynthesis of the polyketide antibiotic mupirocin in *Pseudomonas fluorescens* NCIMB 10586. *Microbiology* 147, 2127–2139.
- Giesbrecht, P., Kersten, T., Maidhof, H., and Wecke, J. (1998). *Staphylococcal* cell wall: morphogenesis and fatal variations in the presence of penicillin. *Microbiol. Mol. Biol. Rev.* 62, 1371–1414.
- Grkovic, S., Brown, M.H., Hardie, K.M., Firth, N., and Skurray, R.A. (2003). Stable low-copy-number *Staphylococcus aureus* shuttle vectors. *Microbiology* 149, 785–794.
- Heath, R.J., and Rock, C.O. (1995). Enoyl-acyl carrier protein reductase (*fabI*) plays a determinant role in completing cycles of fatty acid elongation in *Escherichia coli*. *J. Biol. Chem.* 270, 26538–26542.
- Heath, R.J., and Rock, C.O. (2000). A triclosan-resistant bacterial enzyme. *Nature* 406, 145–146.
- Heath, R.J., Su, N., Murphy, C.K., and Rock, C.O. (2000). The enoyl-acyl carrier protein reductases, *FabI* and *FabL*, from *Bacillus subtilis*. *J. Biol. Chem.* 275, 40128–40133.
- Heath, R.J., White, S.W., and Rock, C.O. (2002). Inhibitors of fatty acid synthesis as antimicrobial chemotherapeutics. *Appl. Microbiol. Biotechnol.* 58, 695–703.
- Kamigiri, K., Suzuki, Y., Shibasaki, M., Morioka, M., Suzuki, K., Tokunaga, T., Setiawan, B., and Rantiatmodjo, R.M. (1996). Kalimantacins A, B and C, novel antibiotics from *Alcaligenes* sp. YL-02632S. I. Taxonomy, fermentation, isolation and biological properties. *J. Antibiot. (Tokyo)* 49, 136–139.
- Klochko, V.V., Kiprianova, E.A., Churkina, L.N., and Avdeeva, L.V. (2008). Antimicrobial spectrum of antibiotic batumin. *Mikrobiol. Z.* 70, 41–46.



- Lu, H., and Tonge, P.J. (2010). Mechanism and inhibition of the FabV enoyl-ACP reductase from *Burkholderia mallei*. *Biochemistry* 49, 1281–1289.
- Massengo-Triassé, R.P., and Cronan, J.E. (2008). *Vibrio cholerae* FabV defines a new class of enoyl-acyl carrier protein reductase. *J. Biol. Chem.* 283, 1308–1316.
- Mattheus, W., Gao, L.-J., Herdewijn, P., Landuyt, B., Verhaegen, J., Masschelein, J., Volckaert, G., and Lavigne, R. (2010). Isolation and purification of a new kalimantacin/batumin-related polyketide antibiotic and elucidation of its biosynthesis gene cluster. *Chem. Biol.* 17, 149–159.
- Payne, D.J., Miller, W.H., Berry, V., Brosky, J., Burgess, W.J., Chen, E., DeWolf, W.E., Jr., Fosberry, A.P., Greenwood, R., Head, M.S., et al. (2002). Discovery of a novel and potent class of FabI-directed antibacterial agents. *Antimicrob. Agents Chemother.* 46, 3118–3124.
- Pidugu, L.S., Kapoor, M., Surolia, N., Surolia, A., and Suguna, K. (2004). Structural basis for the variation in triclosan affinity to enoyl reductases. *J. Mol. Biol.* 343, 147–155.
- Schenk, S., and Laddaga, R.A. (1992). Improved method for electroporation of *Staphylococcus aureus*. *FEMS Microbiol. Lett.* 73, 133–138.
- Smirnov, V.V., Churkina, L.N., Perepnikhatka, V.I., Mukvich, N.S., Garagulia, A.D., Kiprianova, E.A., Kravets, A.N., and Dovzhenko, S.A. (2000). Isolation of highly active strain producing the antistaphylococcal antibiotic batumin. *Prikl. Biokhim. Mikrobiol.* 36, 55–58.
- Tokunaga, T., Kamigiri, K., Orita, M., Nishikawa, T., Shimizu, M., and Kaniwa, H. (1996). Kalimantacin A, B, and C, novel antibiotics produced by *Alcaligenes* sp. YL-02632S. II. Physico-chemical properties and structure elucidation. *J. Antibiot. (Tokyo)* 49, 140–144.
- Xu, H., Sullivan, T.J., Sekiguchi, J., Kirikae, T., Ojima, I., Stratton, C.F., Mao, W., Rock, F.L., Alley, M.R., Johnson, F., et al. (2008). Mechanism and inhibition of saFabI, the enoyl reductase from *Staphylococcus aureus*. *Biochemistry* 47, 4228–4236.
- Zhu, L., Lin, J., Ma, J., Cronan, J.E., and Wang, H. (2010). The triclosan resistance of *Pseudomonas aeruginosa* PA01 is due to FabV, a triclosan-resistant enoyl-acyl carrier protein reductase. *Antimicrob. Agents Chemother.* 54, 689–698.